№ files_lp_3_process_9_67068
File format: docx Character count: 1428 File size: 14 KB
Year: 2024
Region / City: Europe
Topic: Waldenstrom’s Macroglobulinemia, Treatment Approaches
Document Type: Clinical Trial Report
Author: Meletios Dimopoulos, Maria Gavriatopoulou, Efstathios Kastritis, Christian Buske
Target Audience: Medical Researchers, Oncologists, Hematologists
Study Phase: Phase II
Date of Approval: June 2024
Date of Changes: N/A
Primary Endpoint: Achievement of CR / VGPR at 12 and 24 months
Secondary Endpoints: Time to best response, time to first response, time to treatment failure, remission duration, progression free survival, cause specific survival, overall survival, safety, quality of life
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
IBRUTINIB, Capsule 140 mg, Tablet 280 mg, Tablet 420 mg, Imbruvica®, JANSSEN-CILAG PTY LTD
Year: 2023
Region / City: Australia
Theme: Medicine, Oncology
Document Type: Submission Report
Organization / Institution: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: JANSSEN-CILAG PTY LTD
Target Audience: Healthcare professionals, regulators
Period of Validity: Ongoing
Approval Date: 28 March 2023
Modification Date: December 2022
Supplementary Materials: Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition
Note: Year
Topic: Pharmacokinetics, Ibrutinib, CYP3A Inhibition
Document Type: Research Paper
Authors: Eric D. Eisenmann, Qiang Fu, Elizabeth M. Muhowski, Yan Jin, Muhammad Erfan Uddin, Dominique A. Garrison, Robert H. Weber, Jennifer Woyach, John C. Byrd, Alex Sparreboom, Sharyn D. Baker
Target Audience: Researchers, Pharmacologists, Healthcare Professionals
Context: A research paper analyzing the intentional modulation of ibrutinib pharmacokinetics through CYP3A inhibition, including experimental methods and data on the effects of ketoconazole and cobicistat.
Topics: Carflizomib CZAR01 IBRUTINIB